New accelerated approval draft guidance for oncology drugs largely formalizes podium policy that US Food and Drug Administration officials have given in recent months, including strongly recommending randomized clinical trials over single-arm studies.
The guidance, issued on 24 March, states that while single-arm trials may be appropriate in some settings, they can...





